Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 2003 Jun;23(3):365–378. doi: 10.1023/A:1023692705700

Epibatidine: Impact on Nicotinic Receptor Research

Małgorzata Dukat 1, Richard A Glennon 1
PMCID: PMC11530199  PMID: 12825833

Abstract

Epibatidine is a natural product that was isolated and identified by Daly and coworkers in 1992. Since that time, it has had a profound influence on the investigation of α 4β 2 nicotinic cholinergic (nACh) receptor pharmacophore models, and has inspired the development of novel agents with therapeutic potential in CNS disorders. Apart from acetylcholine and nicotine, probably no other agent has had as much recent impact on nACh research as has epibatidine.

Keywords: epibatidine, epiboxidine, nicotine, cholinergic receptors

References

  1. Abreo, M. A., Lin, N. H., Garvey, D. S., Gunn, D. E., Hettinger, A. M., Wasicak, J. T., Pavlik, P. A., Martin, Y. C., Donnelly-Roberts, D. L., Anderson, D. J., Sullivan, J. P., Williams, M., Arneric, S. P., and Holladay, M. W. (1996). Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:817–825. [DOI] [PubMed] [Google Scholar]
  2. Arneric, S. P., and Brioni, J. D. (1999). Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, Wiley, New York, pp. 271–284. [Google Scholar]
  3. Badio, B., and Daly, J. W. (1994). Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:563–569. [PubMed] [Google Scholar]
  4. Badio, B., Garraffo, H. M., Plummer, C. V., Padgett, W. L., and Daly, J. W. (1997). Synthesis and nicotinic activity of epiboxidine: An isoxazole analogue of epibatidine. Eur. J. Pharmacol. 321:189–194. [DOI] [PubMed] [Google Scholar]
  5. Badio, B., Garraffo, H. M., Spande, T. F., and Daly, J. W. (1994). Epibatidine: Discovery and definition as a potent analgesic and nicotine agonist. Med. Chem. Res. 4:440–448. [Google Scholar]
  6. Badio, B., Shi, D., Garraffo, H. M., and Daly, J. W. (1995). Antinociceptive effect of the alkaloid epibatidine: Further studies on involvement of nicotinic receptors. Drug Dev. Res. 36:45–59. [Google Scholar]
  7. Beers, W. H., and Reich, E. (1970). Structure and activity of acetylcholine. Nature (London) 225: 917–922. [DOI] [PubMed] [Google Scholar]
  8. Brown, L. L., Kulkarni, S., Pavlova, O. A., Koren, A. O., Mukhin, A. G., Newman, A. H., and Horti, A. G. (2002). Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J. Med. Chem. 45:2841–2849. [DOI] [PubMed] [Google Scholar]
  9. Campillo, N., Paez, J. A., Alkorta, I., and Goya, P. (1998). A theoretical study of epibatidine. J. Chem. Soc. Perkin Trans. 2:2665–2669. [Google Scholar]
  10. Carroll, F. I., Lee, J. R., Navarro, H. A., Brieaddy, L. E., Abraham, P., Damaj, M. I., and Martin, B. R. (2001b). Synthesis, nicotinic acetylcholine binding, and antinociceptive properties of 2-exo-2-(2′-substituted-3′-phenyl-5′-pyridyl)-7-azabicyclo[2.2.1]heptanes. Novel nicotinic antagonist. J. Med. Chem. 44:4039–4041. [DOI] [PubMed] [Google Scholar]
  11. Carroll, F. I., Liang, F., Navarro, H. A., Brieaddy, L. E., Abraham, P., Damaj, M. I., and Martin, B. R. (2001a). Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues. J. Med. Chem. 44:2229–2237. [DOI] [PubMed] [Google Scholar]
  12. Chen, J., Zhan, C., Stevens, E. D., Izenwasser, S., Wade, D., Chen, S., Paul, D., and Trudell, M. L. (2002). Synthesis and biological evaluation at nicotine acetylcholine receptors of N-arylalkyl-and N-aryl-7-azabicyclo[2.2.1]heptanes. J. Med. Chem. 45:3041–30477. [DOI] [PubMed] [Google Scholar]
  13. Cheng, Y.-X., Dukat, M., Dowd, M., Fiedler, W., Martin, B., Damaj, M. I., and Glennon, R. A. (1999). Synthesis and binding of 6,7,8,9-tetrahydro-5H-pyrido[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors. Eur. J. Med. Chem. 34:177–190. [Google Scholar]
  14. Curtis, L., Chiodini, F., Spang, J. E., Bertrand, S., Patt, J. T., Westera, G., and Bertrand, D. (2000). A new look at the neuronal nicotinic acetylcholine receptor pharmacophore. Eur. J. Pharmacol. 393:155163. [DOI] [PubMed] [Google Scholar]
  15. Daly, J. W. (1995). The chemistry of poisons in amphibian skin. Proc. Nat. Acad. Sci. U.S.A. 92: 9–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Daly, J. W., Garraffo, H. M., Spande, T. F., Decker, M. W., Sullivan, J. P., and Williams, M. (2000). Alkaloids from frog skin: The discovery of epibatidine and the potential for developing novel non-opioid analgesics. Nat. Prod. Rep. 17:131–135. [DOI] [PubMed] [Google Scholar]
  17. Damaj, M. I., Tucker, S. M., Aceto, M. D., and Martin, B. R. (1994). Analgesic activity of epibatidine and its enantiomers in a chemical model of pain. Med. Chem. Res. 4:483–492. [Google Scholar]
  18. Davila-Garcia, M. I., Musachio, J. L., Perry, D. C., Xiao, Y., Horti, A., London, E. D., Dannals, R. F., and Kellar, K. J. (1997). [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J. Pharmacol. Exp. Ther. 282:445–451. [PubMed] [Google Scholar]
  19. Decker, M. W., and Meyer, M. D. (1999). Therapeutic potential of neuronal nicotinic acetylcholine agonists as novel analgesics. Biochem. Pharmacol. 58:917–923. [DOI] [PubMed] [Google Scholar]
  20. Decker, M. W., Meyer, M. D., and Sullivan, J. P. (2001). The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin. Investig. Drugs 10:1819–1830. [DOI] [PubMed] [Google Scholar]
  21. Ding, Y. S., Molina, P. E., Fowler, J. S., Logan, J., Volkow, N. D., Kuhar, M. J., and Carroll, F. I. (1999). Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: Kinetics, nicotine effect, and toxicity. Nucl. Med. Biol. 26:139–148. [DOI] [PubMed] [Google Scholar]
  22. Dukat, M. (1994). 208/210 a.k.a. Epibatidine. Med. Chem. Res. 4:433–439. [Google Scholar]
  23. Dukat, M., Damaj, M. I., Glassco, W., Dumas, D., May, E. L., Martin, B. R., and Glennon, R. A. (1994). Epibatidine: A very high affinity nicotine-receptor ligand. Med. Chem. Res. 4:131–139. [Google Scholar]
  24. Dukat, M., Dowd, M., Damaj, M. I., Martin, B., El-Zahabi, M. A., and Glennon, R. A. (1999). Synthesis, receptor binding, and QSAR studies on 6-subtituted nicotine derivatives as cholinergic ligands. Eur. J. Med. Chem. 34:31–40. [Google Scholar]
  25. Dukat, M., El-Zahabi, M., Ferretti, G., Damaj, M. I., Martin, B. R., and Glennon, R. A. (2002). (–)6-n-Propylnicotine antagonizes the antinociceptive effects of (–)nicotine. Bioorg. Med. Chem. Lett. 12:3005–3007. [DOI] [PubMed] [Google Scholar]
  26. Dukat, M., Herndon, J. L., and Glennon, R. A. (1995). Epibatidine: Reconsideration of the nicotine receptor pharmacophore. NIDA Res. Mono. 162:286. [Google Scholar]
  27. Ellis, J. L., Harman, D., Gonzalez, J., Spera, M. L., Liu, R., Shen, T. Y., Wypij, D. M., and Zuo, F. (1999). Development of muscarinic analgesics derived from epibatidine: Role of the M4 receptor subtype. J. Pharmacol. Exp. Ther. 288:1143–1150. [PubMed] [Google Scholar]
  28. Glennon, R. A., and Dukat, M. (1999). Nicotinic receptor pharmacophores. In Arneric, S. P., and Brioni, J. D. (eds.), Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, Wiley, New York, pp. 271–284. [Google Scholar]
  29. Glennon, R. A., and Dukat, M. (2000). Central nicotinic receptor ligands and pharmacophores. Pharm. Acta Helv. 74:103–114. [DOI] [PubMed] [Google Scholar]
  30. Glennon, R. A. and Dukat, M. (1996). Nicotine recepter ligands. Med. Chem. Res. 6:465–486. [Google Scholar]
  31. Glennon, R. A., Herndon, J. L., and Dukat, M. (1994). Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. 4:461–473. [Google Scholar]
  32. Gundisch, D. (2000). Nicotinic acetylcholine receptors and imaging. Curr. Pharm. Des. 6: 1143–1157. [DOI] [PubMed] [Google Scholar]
  33. Hacksell, U., and Mellin, C. (1989). Stereoselectivity of nicotine isomers. Prog. Brain Res. 79: 95–100. [DOI] [PubMed] [Google Scholar]
  34. Holladay, M. W., Cosford, N. D. P., and McDonald, I. A. (1999). Natural products as a source of nicotinic acetylcholine receptor modulators and leads for drug discovery. In Arneric, S. P., and Brioni, J. D. (Eds.) Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, Wiley, New York, pp. 253–270. [Google Scholar]
  35. Horti, A. G., Scheffel, U., Kimes, A. S., Musachio, J. L., Ravert, H. T., Mathews, W. B., Zhan, Y., Finley, P. A., London, E. D., and Dannals, R. F. (1998). N-[11C]Methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. 41:4199–4206. [DOI] [PubMed] [Google Scholar]
  36. Houghtling, R. A., Davila-Garcia, M. I., Hurt, S. D., and Kellar, K. J. (1994). [3H]Epibatidine binding to nicotinic cholinergic receptors in brain. Med. Chem. Res. 4:538–546. [PubMed] [Google Scholar]
  37. Kim, K. H., Lin, N.-H., and Anderson, D. J. (1996). Quantitative structure–activity relationships of nicotine analogues as neuronal nicotinic acetylcholine receptor ligands. Bioorg. Med. Chem. 4:2211–2217. [DOI] [PubMed] [Google Scholar]
  38. Koren, A. O., Horti, A. G., Mukhin, A. G., Gündisch, D., Kimes, A. S., Dannals, R. F., and London, E. D. (1998). 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J. Med. Chem. 41: 3690–3698. [DOI] [PubMed] [Google Scholar]
  39. Lloyd, G. K., Menzaghi, F., Bontempi, B., Suto, C., Siegel, R., Akong, M., Stauderman, K., Velicelebi, G., Johnson, E., Harpold, M. M., Rao, T. S., Sacaan, A. I., Chavez-Noriega, L. E., Washburn, M. S., Vernier, J. M., Cosford, N. D., and McDonald, I. A. (1998). The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 62:1601–1606. [DOI] [PubMed] [Google Scholar]
  40. MacPherson, R. D. (2000). The pharmacological basis of contemporary pain management. Pharmacol. Ther. 88:163–185. [DOI] [PubMed] [Google Scholar]
  41. Meyer, M. D., Decker, M. W., Rueter, L. E., Anderson, D. J., Dart, M. J., Kim, K. H., Sullivan, J. P., and Williams, M. (2000). The identification of novel structural compound classes for neuronal nicotinic acetylcholine receptors and alangesic efficacy in preclinical models of pain. Eur. J. Pharmacol. 393:171–177. [DOI] [PubMed] [Google Scholar]
  42. Molina, P. E., Ding, Y. S., Carroll, F. I., Liang, F., Volkow, N. D., Pappas, N., Kuhar, M., Abumrad, N., Gatley, S. J., and Fowler, J. S. (1997). Fluoro-norchloroepibatidine: Preclinical assessment of acute toxicity. Nucl. Med. Biol. 24:743–747. [DOI] [PubMed] [Google Scholar]
  43. Nielsen, S. F., Nielsen, E. ø., Olsen, G. M., Liljefors, T., and Peters, D. (2000). Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis. J. Med. Chem. 43:2217–2226. [DOI] [PubMed] [Google Scholar]
  44. Rupniak, N. M., Patel, S., Marwood, R., Webb, J., Traynor, J. R., Elliott, J., Freedman, S. B., Fletcher, S. R., and Hill, R. G. (1994). Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br. J. Pharmacol. 113:1487–1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Schmitt, J. D. (2000). Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem. 7:749–800. [DOI] [PubMed] [Google Scholar]
  46. Sgard, F., Charpantier, E., Bertrand, S., Walker, N., Caput, D., Graham, D., Bertrand, D., and Besnard, F. (2002). A novel human nicotinic receptor subunit, α 10, that confers functionality to the α 9 subunit. Mol. Pharmacol. 61:150–159. [DOI] [PubMed] [Google Scholar]
  47. Sharples, C. G. V., Karig, G., Simpson, G. L., Spenser, J. A., Wright, E., Millar, N. S., Wonnacott, S., and Gallagher, T. (2002). Synthesis and pharmacological characterization of novel analogs of the nicotinic acetylcholine receptor agonist (±)UB-165. J. Med. Chem. 45: 3235–3245. [DOI] [PubMed] [Google Scholar]
  48. Sihver, W., Langstrom, B., and Nordberg, A. (2000a). Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol. Scand. Suppl. 176:27–33. [DOI] [PubMed] [Google Scholar]
  49. Sihver, W., Nordberg, A., Langstrom, B., Mukhin, A. G., Koren, A. O., Kimes, A. S., and London, E. D. (2000b). Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav. Brain Res. 113:143–157. [DOI] [PubMed] [Google Scholar]
  50. Sheridan, R. P., Nilakantan, R., Dixon, J. S., and Venkataraghavan, R. (1986). The ensemble approach to distance geometry: Application to the nicotinic pharmacophore. J. Med. Chem. 29:899–906. [DOI] [PubMed] [Google Scholar]
  51. Spande, T. F., Garraffo, H. M., Edwards, M. W., Yeh, H. J. C., Pannell, L., and Daly, J. W. (1992). Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J. Am. Chem. Soc. 114:3475–3478. [Google Scholar]
  52. Sullivan, J. P., Briggs, C. A., Donnell-Roberts, D., Brioni, J. D., Radek, R. J., McKenna, D. G., Campbell, J. E., Arneric, S. P., Decker, M. W., and Bannon, A. W. (1994a). (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChR). Med. Chem. Res. 4:502–516. [Google Scholar]
  53. Sullivan, J. P., Decker, M. W., Brioni, J. D., Donnelly-Roberts, D., Anderson, D. J., Bannon, A. W., Kang, C. H., Adams, P., Piattoni-Kaplan, M., Buckley, M. J., Gopala-Drichnan, M. Williams, M., and Arneric, S. P. (1994b). (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271: 624–631. [PubMed] [Google Scholar]
  54. Tønder, J. E., Hansen, J. B., Begtrup, M., Petersson, I., Rimvall, K., Christensen, B., Ehrbar, U., and Olessen, P. H. (1999). Improving the nicotinic pharmacophore with a series of (isoxazole)methylene-1-azacyclic compounds. Synthesis, structure–activity relationship, and molecular modeling. J. Med. Chem. 42:4970–4980. [DOI] [PubMed] [Google Scholar]
  55. Tønder, J. E., and Olesen, P. H. (2001). Agonists at α 4β 2 nicotinic acetylcholine receptors: Structure–activity relationships and molecular modeling. Curr. Med. Chem. 8:651–674. [DOI] [PubMed] [Google Scholar]
  56. Tønder, J. E., Olesen, P. H., Hansen, J. B., Begtrup, M., and Pettersson, I. (2001). An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labeled by [3H]-N-methylcarbamylcholine. J. Comp. Aid. Mol. Des. 15:247–258. [DOI] [PubMed] [Google Scholar]
  57. Traynor, J. R. (1998). Epibatidine and pain. Br. J. Anaesth. 81:69–76. [DOI] [PubMed] [Google Scholar]
  58. Villemagne, V. L., Musachio, J. L., and Scheffel, U. (1999). Nicotine and related compounds as PET and SPECT ligands. In Arneric, S. P., and Brioni, J. D. (eds.), Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, Wiley, New York, pp. 235–250. [Google Scholar]
  59. Wright, E., Gallagher, T., Sharples, C. G., and Wonnacott, S. (1997). Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/epibatidine hybrid. Bioorg. Med. Chem. Lett. 7:2867–2870. [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES